Addex Spin-out Neurosterix Closes $105 Million Series B Financing
Neurosterix, a spin-out company from Addex Therapeutics, has successfully closed a $105 million Series B financing round led by leading life science investors. The funding will primarily support Phase 2 clinical development of NTX-253, a selective muscarinic M4 positive allosteric modulator for schizophrenia treatment. Addex retains an 8.5% equity stake valued at $18.6 million and did not participate in the financing.